Pancreatic Cancer Research

ResearcherKyoto Prefectural University of MedicineActive in the last 2 years

Toshifumi Doi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4305-8937; OpenAlex author ID A5030958642, A5101689789. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 8

  1. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  2. Potential Role of Proton Beam Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18260↗
  3. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  4. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  5. Current status of cancer genome medicine for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jjco/hyaf012↗
  6. Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications. Co-author DOI 10.1111/cas.16329↗
  7. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. Co-author DOI 10.1007/s00535-023-01986-9↗
  8. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2017.5399↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshito Itoh · 5 shared papers, 2017–2026 · strength 0.99
  2. Takeshi Ishikawa · 4 shared papers, 2017–2025 · strength 0.76
  3. Tomoki Sakakida · 3 shared papers, 2023–2026 · strength 0.56
  4. Koichi Takayama · 2 shared papers, 2023–2024 · strength 0.33
  5. Akinori Asagi · 2 shared papers, 2025 · strength 0.32
  6. Yohei Kitano · 2 shared papers, 2025 · strength 0.32
  7. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  8. Kunihiro Tsuji · 2 shared papers, 2025 · strength 0.32
  9. Kumiko Umemoto · 2 shared papers, 2025 · strength 0.32
  10. Takeshi Terashima · 2 shared papers, 2025 · strength 0.32
  11. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  12. Satoshi Kobayashi · 2 shared papers, 2025 · strength 0.32
  13. Rei Suzuki · 2 shared papers, 2025 · strength 0.32
  14. Masafumi Ikeda · 2 shared papers, 2025 · strength 0.32
  15. Naohiro Okano · 2 shared papers, 2025 · strength 0.32
  16. Reiko Ashida · 2 shared papers, 2025 · strength 0.32
  17. Kohei Nakachi · 2 shared papers, 2025 · strength 0.32
  18. Hiroaki Nagano · 2 shared papers, 2025 · strength 0.32
  19. Yasuyuki Kawamoto · 2 shared papers, 2025 · strength 0.32
  20. Akihiro Ohba · 2 shared papers, 2025 · strength 0.32
  21. Noritoshi Kobayashi · 2 shared papers, 2025 · strength 0.32
  22. Hiroshi Imaoka · 2 shared papers, 2025 · strength 0.32
  23. Hiroshi Ohyama · 2 shared papers, 2025 · strength 0.32
  24. Junji Furuse · 2 shared papers, 2025 · strength 0.32
  25. Makoto Ueno · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.